This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ford, J. Articles by Milner, J. Search for Related Content PubMed PubMed Citation Articles by Ford, J. Articles by Milner, J.

Cancer-Specific Functions of SIRT1 Enable Human Epithelial Cancer Cell Growth and Survival

YCR P53 Research Laboratory, Department of Biology, University of York, York, United Kingdom

Requests for reprints: Jo Milner, YCR P53 Research Laboratory, Department of Biology, University of York, York YO10 5DD, United Kingdom. Phone: 44-01904-328620; Fax: 44-01904-328322; E-mail: ajm24{at}york.ac.uk.

SIRT1 is a conserved NAD-dependent deacetylase that regulates life span in accord with nutritional provision. In mammalian cells, SIRT1 also down-regulates stress-induced p53 and FoxO pathways for apoptosis, thus favoring survival under stress. The functioning of SIRT1 under normal, nonstressed conditions of cell growth is unknown. Here we have asked if SIRT1 has the capacity to influence cell viability in the absence of applied stress. For this purpose we used synthetic small interfering RNA to silence SIRT1 gene expression by RNA interference (RNAi). We show that the process of RNAi, by itself, does not affect cell growth and is not sufficient to activate a cellular stress response (indicated by lack of activation of endogenous p53). We also show that, in the absence of applied stress, SIRT1 silencing induces growth arrest and/or apoptosis in human epithelial cancer cells. In contrast, normal human epithelial cells and normal human diploid fibroblasts seem to be refractory to SIRT1 silencing. Combined gene knockout with RNAi cosilencing experiments indicate that SIRT1 and Bcl-2 may suppress separable apoptotic pathways in the same cell lineage and that the SIRT1-regulated pathway is independent of p53, Bax, and caspase-2. Alternatively, SIRT1 may suppress apoptosis downstream from these apoptotic factors. In either case, we show that FoxO4 (but not FoxO3) is required as proapoptotic mediator. We further identify caspase-3 and caspase-7 as downstream executioners of SIRT1/FoxO4–regulated apoptosis. Our work identifies SIRT1 as a novel target for selective killing of cancer versus noncancer epithelial cells.

This article has been cited by other articles:

				B. Jung-Hynes and N. Ahmad SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms FASEB J, September 1, 2009; 23(9): 2803 - 2809. [Abstract] [Full Text] [PDF]

				N. Kabra, Z. Li, L. Chen, B. Li, X. Zhang, C. Wang, T. Yeatman, D. Coppola, and J. Chen SirT1 Is an Inhibitor of Proliferation and Tumor Formation in Colon Cancer J. Biol. Chem., July 3, 2009; 284(27): 18210 - 18217. [Abstract] [Full Text] [PDF]

				E. J. Cha, S. J. Noh, K. S. Kwon, C. Y. Kim, B.-H. Park, H. S. Park, H. Lee, M. J. Chung, M. J. Kang, D. G. Lee, et al. Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma Clin. Cancer Res., July 1, 2009; 15(13): 4453 - 4459. [Abstract] [Full Text] [PDF]

				J. Yuan, K. Minter-Dykhouse, and Z. Lou A c-Myc-SIRT1 feedback loop regulates cell growth and transformation J. Cell Biol., April 20, 2009; 185(2): 203 - 211. [Abstract] [Full Text] [PDF]

				N. Pediconi, F. Guerrieri, S. Vossio, T. Bruno, L. Belloni, V. Schinzari, C. Scisciani, M. Fanciulli, and M. Levrero hSirT1-Dependent Regulation of the PCAF-E2F1-p73 Apoptotic Pathway in Response to DNA Damage Mol. Cell. Biol., April 15, 2009; 29(8): 1989 - 1998. [Abstract] [Full Text] [PDF]

				A. A. Tinnikov, K. T. Yeung, S. Das, and H. H. Samuels Identification of a Novel Pathway That Selectively Modulates Apoptosis of Breast Cancer Cells Cancer Res., February 15, 2009; 69(4): 1375 - 1382. [Abstract] [Full Text] [PDF]

				B. Jung-Hynes, M. Nihal, W. Zhong, and N. Ahmad Role of Sirtuin Histone Deacetylase SIRT1 in Prostate Cancer: A TARGET FOR PROSTATE CANCER MANAGEMENT VIA ITS INHIBITION? J. Biol. Chem., February 6, 2009; 284(6): 3823 - 3832. [Abstract] [Full Text] [PDF]

				X.-J. Liang, T. Finkel, D.-W. Shen, J.-J. Yin, A. Aszalos, and M. M. Gottesman SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism Mol. Cancer Res., September 1, 2008; 6(9): 1499 - 1506. [Abstract] [Full Text] [PDF]

				T. Bonome, D. A. Levine, J. Shih, M. Randonovich, C. A. Pise-Masison, F. Bogomolniy, L. Ozbun, J. Brady, J. C. Barrett, J. Boyd, et al. A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer Cancer Res., July 1, 2008; 68(13): 5478 - 5486. [Abstract] [Full Text] [PDF]

				M. Kuningas, M. Putters, R. G. J. Westendorp, P. E. Slagboom, and D. van Heemst SIRT1 Gene, Age-Related Diseases, and Mortality: The Leiden 85-Plus Study J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2007; 62(9): 960 - 965. [Abstract] [Full Text] [PDF]

				D. M. Huffman, W. E. Grizzle, M. M. Bamman, J.-s. Kim, I. A. Eltoum, A. Elgavish, and T. R. Nagy SIRT1 Is Significantly Elevated in Mouse and Human Prostate Cancer Cancer Res., July 15, 2007; 67(14): 6612 - 6618. [Abstract] [Full Text] [PDF]

				H. Huang, K. M. Regan, Z. Lou, J. Chen, and D. J. Tindall CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA Damage Science, October 13, 2006; 314(5797): 294 - 297. [Abstract] [Full Text] [PDF]